# A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

> **NCT06995573** · PHASE1,PHASE2 · RECRUITING · sponsor: **NSC-Therapeutics** · enrollment: 90 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** NSC001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06995573
- **Lead sponsor:** NSC-Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06995573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06995573, "A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06995573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*